David E. Smith

13.0k total citations · 1 hit paper
363 papers, 9.9k citations indexed

About

David E. Smith is a scholar working on Oncology, Molecular Biology and Pharmacology. According to data from OpenAlex, David E. Smith has authored 363 papers receiving a total of 9.9k indexed citations (citations by other indexed papers that have themselves been cited), including 81 papers in Oncology, 55 papers in Molecular Biology and 44 papers in Pharmacology. Recurrent topics in David E. Smith's work include Drug Transport and Resistance Mechanisms (75 papers), Psychedelics and Drug Studies (27 papers) and Antibiotics Pharmacokinetics and Efficacy (23 papers). David E. Smith is often cited by papers focused on Drug Transport and Resistance Mechanisms (75 papers), Psychedelics and Drug Studies (27 papers) and Antibiotics Pharmacokinetics and Efficacy (23 papers). David E. Smith collaborates with scholars based in United States, China and Papua New Guinea. David E. Smith's co-authors include Yongjun Hu, Richard F. Keep, Hong Shen, Donald R. Wesson, Gantt P. Galloway, Paul A. Fisher, Matthias A. Hediger, Thomas Gridley, Frank C. Brosius and Jianming Xiang and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and JAMA.

In The Last Decade

David E. Smith

349 papers receiving 9.3k citations

Hit Papers

Identification, developmental regulation, and response to... 1984 2026 1998 2012 1984 200 400 600

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David E. Smith United States 51 2.8k 1.8k 1.1k 1.0k 945 363 9.9k
P. Eneroth Sweden 50 2.7k 1.0× 796 0.4× 2.0k 1.7× 590 0.6× 483 0.5× 406 11.4k
Karen L. Goa New Zealand 77 3.0k 1.1× 1.9k 1.0× 1.1k 0.9× 2.0k 2.0× 2.4k 2.5× 282 19.1k
Laurence M. Demers United States 60 3.1k 1.1× 2.4k 1.3× 279 0.2× 1000 1.0× 846 0.9× 347 13.3k
David A. Young United Kingdom 61 3.7k 1.3× 896 0.5× 736 0.6× 659 0.6× 1.9k 2.0× 266 12.2k
Thomas Klein United States 66 3.5k 1.3× 1.6k 0.9× 2.1k 1.9× 1.3k 1.3× 4.8k 5.1× 446 15.7k
Lin He China 58 8.2k 2.9× 1.0k 0.6× 1.8k 1.6× 800 0.8× 525 0.6× 513 16.8k
John A. Corbett United States 66 3.4k 1.2× 514 0.3× 792 0.7× 1.1k 1.1× 674 0.7× 224 12.9k
Kym F. Faull United States 65 8.7k 3.1× 1.1k 0.6× 1.4k 1.2× 741 0.7× 1.3k 1.3× 309 17.2k
Richard Schulz Canada 59 4.5k 1.6× 1.4k 0.8× 868 0.8× 1.3k 1.3× 355 0.4× 212 16.9k
V. Marks United Kingdom 54 2.5k 0.9× 726 0.4× 871 0.8× 1.3k 1.3× 905 1.0× 441 12.1k

Countries citing papers authored by David E. Smith

Since Specialization
Citations

This map shows the geographic impact of David E. Smith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David E. Smith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David E. Smith more than expected).

Fields of papers citing papers by David E. Smith

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David E. Smith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David E. Smith. The network helps show where David E. Smith may publish in the future.

Co-authorship network of co-authors of David E. Smith

This figure shows the co-authorship network connecting the top 25 collaborators of David E. Smith. A scholar is included among the top collaborators of David E. Smith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David E. Smith. David E. Smith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
2.
Briggs, Emily, Mohamed Kamal, Matthew P. Kosloski, et al.. (2023). Integrated Exposure–Response of Dupilumab in Children, Adolescents, and Adults With Atopic Dermatitis Using Categorical and Continuous Efficacy Assessments: A Population Analysis. Pharmaceutical Research. 40(11). 2653–2666. 1 indexed citations
3.
Braverman, Eric R., Mark S. Gold, Abdalla Bowirrat, et al.. (2022). Proposing a “Brain Health Checkup (BHC)” as a Global Potential “Standard of Care” to Overcome Reward Dysregulation in Primary Care Medicine: Coupling Genetic Risk Testing and Induction of “Dopamine Homeostasis”. International Journal of Environmental Research and Public Health. 19(9). 5480–5480. 7 indexed citations
4.
Blum, Kenneth, Lisa Lott, Marjorie C. Gondré‐Lewis, et al.. (2021). High Genetic Addiction Risk Score (GARS) in Chronically Prescribed Severe Chronic Opioid Probands Attending Multi-pain Clinics: an Open Clinical Pilot Trial. Molecular Neurobiology. 58(7). 3335–3346. 23 indexed citations
5.
Boyett, Brent, Rajendra D. Badgaiyan, Panayotis K. Thanos, et al.. (2020). Addiction by Any Other Name is Still Addiction: Embracing Molecular Neurogenetic/Epigenetic Basis of Reward Deficiency. PubMed. 6(1). 1–4. 7 indexed citations
7.
Paka, Latha, David E. Smith, Dawoon Jung, et al.. (2017). Anti-steatotic and anti-fibrotic effects of the KCa3.1 channel inhibitor, Senicapoc, in non-alcoholic liver disease. World Journal of Gastroenterology. 23(23). 4181–4181. 17 indexed citations
8.
Shen, Hong, et al.. (2015). Population pharmacokinetic modeling of cefadroxil renal transport in wild-type andPept2knockout mice. Xenobiotica. 46(4). 342–349. 5 indexed citations
9.
Johnson, Dennis L., et al.. (2012). Water-Refined Solution Structure of the Human Grb7-SH2 Domain in Complex with the erbB2 Receptor Peptide pY1139. Protein and Peptide Letters. 19(8). 832–838.
10.
Smith, David E., Gantt P. Galloway, & Richard B. Seymour. (2011). Methamphetamine Abuse, Violence, and Appropriate Treatment. Valparaiso University law review. 31(2). 661–667.
11.
Smith, David E.. (2006). An Upper/Downer Perfect Storm: The Coming World-Wide Drug Epidemic. Journal of Psychoactive Drugs. 38(4). 535–536. 1 indexed citations
12.
Smith, David E., et al.. (2001). Viscosity and freezing point of a reduced fat ice cream mix as related to inulin content. Milk science international/Milchwissenschaft. 56(1). 25–29. 32 indexed citations
13.
Smith, David E., et al.. (1993). Comparison of the predictive ability of ice cream freezing point depression equations. Milk science international/Milchwissenschaft. 48(12). 671–675. 5 indexed citations
14.
Swetz, Frank & David E. Smith. (1987). Capitalism and arithmetic : the new math of the 15th century, including the full text of the Treviso arithmetic of 1478, translated by David Eugene Smith. 33 indexed citations
15.
Smith, David E., et al.. (1986). [Effect of sweetener/stabilizer interactions on the viscosity and freezing point of ice cream mix]. [English]. Milk science international/Milchwissenschaft. 41(12). 766–769. 4 indexed citations
16.
Smith, David E.. (1986). Cocaine-Alcohol Abuse: Epidemiological, Diagnostic and Treatment Considerations. Journal of Psychoactive Drugs. 18(2). 117–129. 51 indexed citations
17.
Smith, David E., et al.. (1984). Changes in freezing point and rheological properties of ice cream mix as a function of sweetener system and whey substitution. Milk science international/Milchwissenschaft. 39(8). 455–457. 23 indexed citations
18.
Smith, David E. & Donald R. Wesson. (1983). Benzodiazepine Dependency Syndromes. Journal of Psychoactive Drugs. 15(1-2). 85–95. 69 indexed citations
19.
Smith, David E., et al.. (1978). Master Open Day Econometrics and Management Science. PubMed. 229–40. 21 indexed citations
20.
Gay, George R., David E. Smith, Donald R. Wesson, & C. W. Sheppard. (1972). Outpatient Barbiturate Withdrawal Using Phenobarbital. International Journal of the Addictions. 7(1). 17–26. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026